AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 OCT 11 - (NewsRx.com & NewsRx.net) --
by Sonia Nichols, senior medical writer - Short-term, high-dose tamoxifen therapy attacks cervical cancers on several fronts, researchers in Rome, Italy, report.
The authors of a new study list angiogenesis, apoptosis, and proliferation as factors controlled by tamoxifen when it is administered at high doses for five days to women with either estrogen (ER) positive or ER negative cervical tumors.
To understand the effects of altering standard tamoxifen regimens on biochemical parameters in cancer patients, researchers in Rome, Italy, at the Catholic University and the University of Rome Tor Vergata enrolled 24 women with cervical cancer in a limited clinical trial. At baseline, biopsy results revealed that about half of the women had ER positive tumors. Randomizing patients in both ER positive and ER negative groups to receive either 80 mg or 160 mg of tamoxifen per day for 5 days, investigators performed follow-up biopsies after treatment ended.
Ki67, marking cell proliferation activity, was lower after tamoxifen therapy. Prior to therapy, Ki67 indices were similar regardless of ER status. After therapy, there were greater percentage reductions of Ki67 in ER-positive cells than in ER-negative cells, according to Gabriella Ferrandina and team, Catholic University ("Tamoxifen modulates the expression of Ki67, apoptosis, and microvessel density in cervical cancer," Clinical Cancer Research, September 2001;2656-2661).
"Microvessel density values in pre-tamoxifen biopsies were significantly higher than corresponding values in posttreatment ...
Source: HighBeam Research, Tamoxifen Attacks Cellular Processes In Gynecological Tumors.(Brief...